BioCryst Q3: ORLADEYO revenue $116.3M (+35.7%); raises FY total revenue guide to $443-448M

BIOCRYST PHARMACEUTICALS INC

2024-Q3 EPS reported -$0.30 revenue$319,178,000

Q3 total revenue $117.1M (+35.1% yoy) led by ORLADEYO net revenue of $116.3M.
GAAP operating profit of $7.7M vs. loss of $11.9M in Q3 2023; non-GAAP op. profit $24.9M.
Net loss narrowed to $14.0M ($0.07 per share) from $36.1M ($0.19) a year ago.
FY 2024 ORLADEYO revenue guidance raised to $430-435M (top end of prior range); total revenue $443-448M.
Pipeline: BCX17725 for Netherton syndrome entered clinic; avoralstat for DME on track for 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.